The addition of anti-PD-1 and agonist OX40 antibodies to the vaccine resulted in durable tumor regression and a survival benefit, which was associated with the reduced coexpression of the T-cell exhaustion markers Lag3 and PD-1 by OX40-targeted therapy [195]. The gene discussed is TNFRSF4; the disease is neoplasm.